Vaccines

An overview and update

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Vaccines prevent death on a large scale, but only if enough people are immunised. If most of the people within a population are vaccinated against an infection, those who are not will still be protected because spread of the pathogen is blocked. This is known as “herd immunity”. However, this immunity relies on public support of vaccination programmes which, in turn, strongly depends on perception of risk versus benefit. For example, the controversy relating to the safety of the combined measles, mumps and rubella (MMR) vaccine stemming from proposed links with autism has had a detrimental impact on the protection of children from these diseases within the UK. While most of the researchers who initially proposed this link subsequently retracted their speculations, the damage in terms of public confidence was done. A marked reduction in the percentage of the population immunised against MMR (from 92 to 82 per cent) occurred across the UK, with some areas of London reporting an uptake 20 per cent lower than the national average.1 The World Health Organization recommends an immunity level of 95 per cent to prevent disease outbreaks. The reduction in MMR vaccinations has been reflected by increased reports of measles and mumps in the UK and, in response, some health authorities are holding publicity events and training primary care staff to encourage uptake of the combined vaccine.
Original languageEnglish
Pages (from-to)209-212
Number of pages4
JournalPharmaceutical Journal
Volume276
Issue number7388
Publication statusPublished - 1 Feb 2010

Fingerprint

Mumps
Measles
Combined Vaccines
Vaccines
Rubella
Immunity
Vaccination
Herd Immunity
Measles-Mumps-Rubella Vaccine
Autistic Disorder
Population
Disease Outbreaks
Primary Health Care
Research Personnel
Safety
Health
Infection

Keywords

  • vaccines
  • MMR
  • herd immunity

Cite this

Perrie, Yvonne. / Vaccines : An overview and update. In: Pharmaceutical Journal. 2010 ; Vol. 276, No. 7388. pp. 209-212.
@article{48ba7d631fda4f7480ec4198bd047b81,
title = "Vaccines: An overview and update",
abstract = "Vaccines prevent death on a large scale, but only if enough people are immunised. If most of the people within a population are vaccinated against an infection, those who are not will still be protected because spread of the pathogen is blocked. This is known as “herd immunity”. However, this immunity relies on public support of vaccination programmes which, in turn, strongly depends on perception of risk versus benefit. For example, the controversy relating to the safety of the combined measles, mumps and rubella (MMR) vaccine stemming from proposed links with autism has had a detrimental impact on the protection of children from these diseases within the UK. While most of the researchers who initially proposed this link subsequently retracted their speculations, the damage in terms of public confidence was done. A marked reduction in the percentage of the population immunised against MMR (from 92 to 82 per cent) occurred across the UK, with some areas of London reporting an uptake 20 per cent lower than the national average.1 The World Health Organization recommends an immunity level of 95 per cent to prevent disease outbreaks. The reduction in MMR vaccinations has been reflected by increased reports of measles and mumps in the UK and, in response, some health authorities are holding publicity events and training primary care staff to encourage uptake of the combined vaccine.",
keywords = "vaccines, MMR, herd immunity",
author = "Yvonne Perrie",
year = "2010",
month = "2",
day = "1",
language = "English",
volume = "276",
pages = "209--212",
journal = "Pharmaceutical Journal",
issn = "0031-6873",
number = "7388",

}

Perrie, Y 2010, 'Vaccines: An overview and update', Pharmaceutical Journal, vol. 276, no. 7388, pp. 209-212.

Vaccines : An overview and update. / Perrie, Yvonne.

In: Pharmaceutical Journal, Vol. 276, No. 7388, 01.02.2010, p. 209-212.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vaccines

T2 - An overview and update

AU - Perrie, Yvonne

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Vaccines prevent death on a large scale, but only if enough people are immunised. If most of the people within a population are vaccinated against an infection, those who are not will still be protected because spread of the pathogen is blocked. This is known as “herd immunity”. However, this immunity relies on public support of vaccination programmes which, in turn, strongly depends on perception of risk versus benefit. For example, the controversy relating to the safety of the combined measles, mumps and rubella (MMR) vaccine stemming from proposed links with autism has had a detrimental impact on the protection of children from these diseases within the UK. While most of the researchers who initially proposed this link subsequently retracted their speculations, the damage in terms of public confidence was done. A marked reduction in the percentage of the population immunised against MMR (from 92 to 82 per cent) occurred across the UK, with some areas of London reporting an uptake 20 per cent lower than the national average.1 The World Health Organization recommends an immunity level of 95 per cent to prevent disease outbreaks. The reduction in MMR vaccinations has been reflected by increased reports of measles and mumps in the UK and, in response, some health authorities are holding publicity events and training primary care staff to encourage uptake of the combined vaccine.

AB - Vaccines prevent death on a large scale, but only if enough people are immunised. If most of the people within a population are vaccinated against an infection, those who are not will still be protected because spread of the pathogen is blocked. This is known as “herd immunity”. However, this immunity relies on public support of vaccination programmes which, in turn, strongly depends on perception of risk versus benefit. For example, the controversy relating to the safety of the combined measles, mumps and rubella (MMR) vaccine stemming from proposed links with autism has had a detrimental impact on the protection of children from these diseases within the UK. While most of the researchers who initially proposed this link subsequently retracted their speculations, the damage in terms of public confidence was done. A marked reduction in the percentage of the population immunised against MMR (from 92 to 82 per cent) occurred across the UK, with some areas of London reporting an uptake 20 per cent lower than the national average.1 The World Health Organization recommends an immunity level of 95 per cent to prevent disease outbreaks. The reduction in MMR vaccinations has been reflected by increased reports of measles and mumps in the UK and, in response, some health authorities are holding publicity events and training primary care staff to encourage uptake of the combined vaccine.

KW - vaccines

KW - MMR

KW - herd immunity

UR - http://www.pharmaceutical-journal.com/learning/learning-article/vaccines-an-overview-and-update/10997378.article

M3 - Article

VL - 276

SP - 209

EP - 212

JO - Pharmaceutical Journal

JF - Pharmaceutical Journal

SN - 0031-6873

IS - 7388

ER -